Antiagregant treatments;Anti̇agregan tedavi̇ler

Turk Beyin Damar Hastaliklar Dergisi

Volumn 18, Issue 1, 2012, Pages 1-5

  Uzuner, Nevzat ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Antiagregant treatment; Aspirin; Atherothrombosis; Clopidogrel

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; DRUG EFFICACY; DRUG MECHANISM; PATHOGENESIS; REVIEW; THROMBOSIS;

EID: 84868575427     PISSN: 13011375     EISSN: None     Source Type: Journal    
DOI: 10.5505/tbdhd.2012.08208     Document Type: Review

References (26)

1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25(14):1197-1207. (Pubitemid 38891569)
2. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl JMed. 2007;357(24):2482-2494.
3. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):403-412.
4. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814. (Pubitemid 41716567)
5. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997 May 31; 349 (9065): 1569- 81.
6. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997 Jun 7; 349 (9066): 1641-9.
7. Centocor I. Centocor, Inc. And Eli Lilly and Company Halt Phase 3Trial Of Reopro For Stroke. October 28, 2005. Availableat: ttp://biospace.com/news- story.aspx?StoryID-853&full-1.
8. European Stroke Organisation Executive Committee (2008)Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457-507
9. Antithrombotic Trialists' Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in highrisk patients. BMJ 2002; 324: 71-86.
10. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Lancet (2006) 367:1665-1673
11. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368-80. (Pubitemid 46742325)
12. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extendedrelease dipyridamole versus clopidogrel for recurrent stroke.N Engl J Med 2008;359:1238-51.
13. Bath PM, Cotton D, Martin RH, et al. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke 2010;41:732-8.
14. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
15. CURE Steering Committee. Effects of clopidogrel in addition to aspirin inpatients with acute coronary syndromes without STsegment elevation. N Big/ J Med 2001;345:494-502.
16. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331e7.
17. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
18. Aw D, Sharma JC. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice? Postgrad Med J 2012; 88: 34-37.
19. Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. (Review)Copyright © 2011 The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd.
20. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76.
21. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Pubitemid 350106708)
22. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
23. Goto S, Ogawa H, Takeuchi M, et al. Double-blind, placebo-controlledphase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high risk coronary artery disease. Eur Heart J. 2010;31(21):2601-2613.
24. O'Donoghue M. LANCELOT ACS: a prospective, randomized, doubleblind, placebo-controlled trial of a reversible PAR-1 thrombin receptor antagonist in patients with acute coronary syndromes. Presented at the 2010 TCT Congress. September 21- 25, 2010. Washington, DC.
25. Fintel DJ. Vasc Health and Risk Management 2012; 8: 77-89.
26. Schwarting M. Interim review alters phase III studies of novel antithrombotic therapy. Available from: https://www.dcri.org/news-publications/ news/2011-news-archives/ interim-review-alters-phase-iii-studiesof-novel- antithrombotictherapy? searchterm-vorapaxar.